Edesa Biotech Inc has a consensus price target of $39, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on February 14, 2024, November 29, 2023, and November 22, 2023. With an average price target of $17.33 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 312.70% upside for Edesa Biotech Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/14/2024 | EDSA | Buy Now | Edesa Biotech | $4.20 | 400% | HC Wainwright & Co. | Vernon Bernardino | → $21 | Reiterates | Buy → Buy | Get Alert |
11/29/2023 | EDSA | Buy Now | Edesa Biotech | $4.20 | 400% | HC Wainwright & Co. | Vernon Bernardino | $70 → $21 | Maintains | Buy | Get Alert |
11/22/2023 | EDSA | Buy Now | Edesa Biotech | $4.20 | 138.1% | HC Wainwright & Co. | Vernon Bernardino | → $10 | Reiterates | Buy → Buy | Get Alert |
10/12/2023 | EDSA | Buy Now | Edesa Biotech | $4.20 | 1257.14% | Brookline Capital | Kemp Dolliver | → $57 | Maintains | Buy | Get Alert |
08/15/2023 | EDSA | Buy Now | Edesa Biotech | $4.20 | 138.1% | HC Wainwright & Co. | Vernon Bernardino | $112 → $70 | Maintains | Buy | Get Alert |
05/24/2023 | EDSA | Buy Now | Edesa Biotech | $4.20 | 280.95% | HC Wainwright & Co. | Vernon Bernardino | → $112 | Reiterates | Buy → Buy | Get Alert |
03/15/2023 | EDSA | Buy Now | Edesa Biotech | $4.20 | 280.95% | HC Wainwright & Co. | Vernon Bernardino | → $112 | Reiterates | → Buy | Get Alert |
02/14/2023 | EDSA | Buy Now | Edesa Biotech | $4.20 | 280.95% | HC Wainwright & Co. | Vernon Bernardino | → $112 | Reiterates | → Buy | Get Alert |
12/16/2022 | EDSA | Buy Now | Edesa Biotech | $4.20 | 209.52% | Brookline Capital | Kemp Dolliver | → $13 | Maintains | Buy | Get Alert |
12/20/2021 | EDSA | Buy Now | Edesa Biotech | $4.20 | 280.95% | HC Wainwright & Co. | Vernon Bernardino | — | Initiates | → Buy | Get Alert |
The latest price target for Edesa Biotech (NASDAQ: EDSA) was reported by HC Wainwright & Co. on February 14, 2024. The analyst firm set a price target for $21.00 expecting EDSA to rise to within 12 months (a possible 400.00% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Edesa Biotech (NASDAQ: EDSA) was provided by HC Wainwright & Co., and Edesa Biotech reiterated their buy rating.
There is no last upgrade for Edesa Biotech.
There is no last downgrade for Edesa Biotech.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edesa Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edesa Biotech was filed on February 14, 2024 so you should expect the next rating to be made available sometime around February 14, 2025.
While ratings are subjective and will change, the latest Edesa Biotech (EDSA) rating was a reiterated with a price target of $0.00 to $21.00. The current price Edesa Biotech (EDSA) is trading at is $4.20, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.